About panbela therapeutics inc - PBLA
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
PBLA At a Glance
Panbela Therapeutics, Inc.
712 Vista Boulevard
Waconia, Minnesota 55387
| Phone | 1-952-479-1196 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -25,263,000.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
PBLA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.18 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 1.128 |
PBLA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,157,875.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PBLA Liquidity
| Current Ratio | 0.248 |
| Quick Ratio | 0.248 |
| Cash Ratio | 0.209 |
PBLA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -301.108 |
| Return on Equity | N/A |
| Return on Total Capital | -5,219.628 |
| Return on Invested Capital | N/A |
PBLA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,073.14 |
| Total Debt to Total Assets | 44.009 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 866.529 |